Cargando…

Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future

PURPOSE OF REVIEW: Guidelines for the management of large vessel vasculitides have been recently updated by several scientific societies. We have evaluated the current recommendations for treatment of giant cell arteritis (GCA) and Takayasu arteritis (TA) and addressed potential future therapeutic s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hellmich, B., Águeda, A. F., Monti, S., Luqmani, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Recent Advances in Large Vessel Vasculitis ( C Dejaco and C Duftner, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549425/ https://www.ncbi.nlm.nih.gov/pubmed/33044642 http://dx.doi.org/10.1007/s11926-020-00964-x

Ejemplares similares

Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis
por: Palmowski, Andriko, et al.
Publicado: (2020)

Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel Vasculitides
por: Schäfer, Valentin Sebastian, et al.
Publicado: (2020)

Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?
por: Toyoda, Task, et al.
Publicado: (2022)

Advances in the Treatment of Behcet’s Disease
por: Alibaz-Oner, Fatma, et al.
Publicado: (2021)

ANCA Status or Clinical Phenotype — What Counts More?
por: Windpessl, Martin, et al.
Publicado: (2021)

Patient Reported Outcomes in Large Vessel Vasculitides
por: Robson, Joanna, et al.
Publicado: (2021)

Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides
por: Tombetti, Enrico, et al.
Publicado: (2021)

Localized Forms of Vasculitis
por: Martins-Martinho, Joana, et al.
Publicado: (2021)

The Nasal Microbiome in ANCA-Associated Vasculitis: Picking the Nose for Clues on Disease Pathogenesis
por: Dekkema, G. J., et al.
Publicado: (2021)

Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases
por: Lötscher, Fabian, et al.
Publicado: (2022)

Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases
por: Seitz, Luca, et al.
Publicado: (2022)

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis
por: Águeda, Ana F, et al.
Publicado: (2019)

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2019)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
por: Mekinian, Arsène, et al.
Publicado: (2023)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
por: Goodfellow, Nicola, et al.
Publicado: (2017)

Safe use of tocilizumab in pregnant women with Takayasu arteritis: three case studies
por: Konagai, Nao, et al.
Publicado: (2023)

Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care
por: Molina-Collada, Juan, et al.
Publicado: (2023)

Need and value of targeted immunosuppressive therapy in giant cell arteritis
por: Sandovici, Maria, et al.
Publicado: (2022)

Validity of the EULAR recommendations on the use of ultrasound in the diagnosis of giant cell arteritis
por: Fernández-Fernández, Elisa, et al.
Publicado: (2022)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis
por: Jud, Philipp, et al.
Publicado: (2023)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis
por: Adriawan, Ignatius Ryan, et al.
Publicado: (2022)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force
por: Sanchez-Alvarez, Catalina, et al.
Publicado: (2023)

Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study
por: Mensch, Noemi, et al.
Publicado: (2023)

Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case–control study
por: Turkiewicz, Aleksandra, et al.
Publicado: (2020)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2022)

Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis
por: Pacoureau, Lucas, et al.
Publicado: (2023)

Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence?
por: De Smit, Elisabeth, et al.
Publicado: (2017)

Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme
por: Chrysidis, Stavros, et al.
Publicado: (2020)

Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
por: De Miguel, Eugenio, et al.
Publicado: (2022)

Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
por: Esen, Idil, et al.
Publicado: (2023)

Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids
por: Estupiñán-Moreno, Elkyn, et al.
Publicado: (2022)

Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis
por: Lai, Lana Yin Hui, et al.
Publicado: (2018)

Distribution patterns of arterial affection and the influence of glucocorticoids on (18)F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis
por: Malich, Leander, et al.
Publicado: (2022)

External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic
por: van Nieuwland, Marieke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6ccimbi8ge40k2on3b4338kvsn